Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Neuropace, Inc. Common Stock

NPCE

NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.

Last trade $8.24
Day change +$0.27 (+3.39%)
Day range $7.61 – $8.69
Volume 384,473
Market cap $275M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$274.58M
Price / earnings
—
Price / book
23.89×
Price / sales
2.9×
EV / sales
3.42×
EV / EBITDA
-22.67×

Profitability

Earnings per share
-$0.55
Return on assets
-19.96%
Return on equity
-164.6%
Dividend yield
0%

Liquidity and leverage

Debt / equity
5.15×
Current ratio
5.26×
Quick ratio
4.09×
Cash ratio
0.64×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$12.42M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for NPCE, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$23.1M$22.83M$22.07M$26.59M$23.35M$19.5M$22.52M$21.47M
Cost of revenue$3.63M$3.92M$4.02M$6.01M$4.18M$3.29M$5.18M$5.28M
Gross profit$19.47M$18.91M$18.05M$20.58M$19.17M$16.21M$17.34M$16.19M
Selling, general and administrative$15.39M$17.15M$16.43M$15.32M$16.62M$17.56M$15.05M$13.79M
Research and development$6.17M$6.9M$7.19M$7.03M$6.58M$6.85M$7.44M$6.05M
Total operating expenses$21.55M$24.05M$23.62M$22.35M$23.2M$24.4M$22.49M$19.84M
Operating income-$2.08M-$5.14M-$5.57M-$1.77M-$4.03M-$8.19M-$5.15M-$3.65M
Interest expense-$1.57M-$1.54M-$1.52M-$1.6M-$1.65M-$2.06M-$2.15M-$2.19M
Income before taxes-$3.3M-$6.2M-$6.69M-$2.73M-$4.92M-$10.02M-$6.59M-$5.25M
Income taxes$0$0$0$0$0$0$0$0
Net income-$3.3M-$6.2M-$6.69M-$2.73M-$3.5M-$8.65M-$6.59M-$5.25M
Net income attributable to common shareholders-$3.3M-$6.2M-$6.69M-$2.73M-$3.5M-$8.65M-$6.59M-$5.25M
EBITDA-$2M-$5.08M-$5.51M-$1.69M-$3.97M-$8.13M-$5.1M-$3.61M
Basic earnings per share-$0.10-$0.18-$0.20-$0.08-$0.11-$0.26-$0.21-$0.18
Diluted earnings per share-$0.10-$0.18-$0.20-$0.08-$0.11-$0.26-$0.21-$0.18

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

NeuroPace, Inc. (NPCE) Reports Q3 Loss, Misses Revenue Estimates

NeuroPace (NPCE) reported a quarterly loss of $0.03 per share, beating consensus estimates of $0.06 loss by 50%, but missed revenue expectations with $23.1 million versus the estimated $26.9 million. The company has underperformed the S&P 500 by 30.2% year-to-date. With mixed estimate revisions, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.

Zacks Investment Research

Treace Medical Concepts (TMCI) Reports Q3 Loss, Tops Revenue Estimates

Treace Medical Concepts reported a Q3 loss of $0.19 per share, beating consensus estimates of $0.26 loss by 26.92%. Revenue of $48.25 million slightly exceeded estimates by 1.18%, though it declined from $50.21 million year-over-year. The stock has gained 70.6% year-to-date but carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions.

Zacks Investment Research

CVRx (CVRX) Reports Q3 Loss, Lags Revenue Estimates

CVRx reported a quarterly loss of $0.52 per share, missing the consensus estimate of $0.49, with revenues of $13.83 million also falling short of expectations. The stock has declined 77.8% year-to-date, significantly underperforming the S&P 500's 12.3% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.

Zacks Investment Research

Alcon (ALC) Surges 6.8%: Is This an Indication of Further Gains?

Alcon (ALC) shares surged 6.8% to $77.31 on investor optimism ahead of its third quarter 2026 earnings release on November 11. The company is expected to report EPS of $0.89 (up 12.7% YoY) and revenues of $2.73 billion (up 5.6% YoY). However, with unchanged earnings estimate revisions over the past 30 days, analysts caution that the stock may struggle to maintain momentum without further positive estimate revisions. NeuroPace (NPCE), a peer in the medical instruments industry, also gained 8.4% but remains down 2.8% over the past month.

Zacks Investment Research

Neuronetics (STIM) Reports Q3 Loss, Tops Revenue Estimates

Neuronetics (STIM) reported a quarterly loss of $0.02 per share, beating the consensus estimate of $0.08 loss by 75%, with revenues of $41.96 million exceeding expectations by 3.10%. The stock has gained 63.8% year-to-date, outperforming the S&P 500's 10.6% gain. However, the company received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.